In this issue of Blood, Li et al(1) show that detection of leukemic stem cells (LSCs) may predict relapse and overall survival (OS) after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML) better than classical measurable residual disease (MRD) by multiparameter flow cytometry (MFC).
Voso, M.t., Buccisano, F. (2022). AML: making residual disease more measurable. BLOOD, 140(5), 415-417 [10.1182/blood.2022017138].
AML: making residual disease more measurable
Voso, Maria Teresa;Buccisano, Francesco
2022-01-01
Abstract
In this issue of Blood, Li et al(1) show that detection of leukemic stem cells (LSCs) may predict relapse and overall survival (OS) after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML) better than classical measurable residual disease (MRD) by multiparameter flow cytometry (MFC).File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
